Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent Claudication.

Alan T. Hirsch1, Laura M Reich

  • 1Vascular Medicine Program, Cardiovascular Division, Minnesota Vascular Diseases Center, University of Minnesota Medical School, Mayo Mail Code 508, 420 Delaware Street, SE, Minneapolis, MN 55455, USA. Hirsc005@tc.umn.edu

Current Treatment Options in Cardiovascular Medicine
|May 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ankle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort.

Vascular medicine (London, England)·2007
Same author

Role of the geneticist in testing and counseling for inherited thrombophilia.

Genetics in medicine : official journal of the American College of Medical Genetics·2003
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Peripheral arterial disease (PAD) management requires treating limb symptoms and systemic atherosclerosis. Exercise, medication, and revascularization improve claudication, while risk factor control and antiplatelet therapy reduce cardiovascular events.

Area of Science:

  • Vascular Medicine
  • Cardiovascular Surgery
  • Interventional Cardiology

Background:

  • Intermittent claudication is the primary symptom of peripheral arterial disease (PAD).
  • Effective PAD management necessitates addressing both limb-specific symptoms and underlying systemic atherosclerosis.
  • Untreated PAD increases functional impairment, amputation risk, and cardiovascular ischemic events like myocardial infarction and stroke.

Purpose of the Study:

  • To outline comprehensive treatment strategies for peripheral arterial disease (PAD).
  • To detail management of intermittent claudication symptoms and reduce cardiovascular risk.
  • To emphasize the importance of risk factor modification and antiplatelet therapy in all PAD patients.

Main Methods:

  • Non-invasive and invasive revascularization techniques (endovascular and surgical) for high-grade stenoses.

Related Experiment Videos

  • Pharmacotherapeutic interventions, including cilostazol, to alleviate exertional limb symptoms.
  • Supervised exercise programs and comprehensive atherosclerosis risk factor normalization (smoking cessation, glycemic control, blood pressure, and LDL cholesterol management).

    • Main Results:

    • Supervised exercise and pharmacotherapy effectively decrease exertional limb symptoms in most claudication patients.
    • Endovascular revascularization is effective for proximal limb arterial stenoses.
    • Surgical revascularization is reserved for severe aortoiliac disease with low perioperative risk.
    • Risk factor modification and antiplatelet therapy are crucial for all PAD patients to reduce cardiovascular events.

    Conclusions:

    • A multi-faceted approach combining lifestyle changes, medication, and revascularization is essential for managing PAD.
    • Aggressive management of atherosclerosis risk factors and consistent antiplatelet therapy are paramount in preventing major adverse cardiovascular events.
    • Successful PAD treatment improves quality of life, reduces amputation rates, and mitigates systemic cardiovascular risks.